Mesoblast Limited (NASDAQ: MESO)
$7.61
-0.0400 ( -0.52% ) 204.6K
Mesoblast Ltd is a clinical-stage biotechnology company. It develops and commercializes innovative allogeneic cellular medicines to treat complex diseases resistant to the conventional standard of care. Its portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) and others.
Market Data
Open
$7.61
Previous close
$7.65
Volume
204.6K
Market cap
$875.33M
Day range
$7.35 - $7.86
52 week range
$1.61 - $10.24
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 4 | Mar 27, 2024 |
6-k | Quarterly Reports | 34 | Mar 21, 2024 |
6-k | Quarterly Reports | 4 | Mar 15, 2024 |
6-k | Quarterly Reports | 5 | Mar 12, 2024 |
6-k | Quarterly Reports | 47 | Mar 01, 2024 |
6-k | Quarterly Reports | 99 | Feb 29, 2024 |
6-k | Quarterly Reports | 5 | Feb 21, 2024 |
6-k | Quarterly Reports | 13 | Feb 01, 2024 |
6-k | Quarterly Reports | 5 | Jan 23, 2024 |
6-k | Quarterly Reports | 29 | Jan 16, 2024 |